Previous 10 | Next 10 |
ALACHUA and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate i...
ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 202...
2023-06-23 02:49:25 ET Summary AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9% respectively. However, the lack of earnings a...
ALACHUA, Fla. and TAMPA, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will particip...
ALACHUA, Fla. and TAMPA, Fla., May 12, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will pa...
2023-05-09 10:58:07 ET AxoGen, Inc. (AXGN) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Ed Joyce – Director-Investor Relations Karen Zaderej – Chairman, Chief Executive Officer and President Pete Mariani – Exec...
2023-05-09 07:09:27 ET AxoGen press release ( NASDAQ: AXGN ): Q1 GAAP EPS of -$0.10 beats by $0.12 . Revenue of $36.7M (+18.4% Y/Y) beats by $1.24M . Management continues to expect full-year 2023 revenue to be in the range of $154 million to $159 million vs $15...
ALACHUA, Fla. and TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31,...
2023-05-08 13:31:39 ET AxoGen ( NASDAQ: AXGN ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.14 (+30.0% Y/Y) and the consensus Revenue Estimate is $35.46M (+14.4% Y/Y). Over the last 2 years, AXG...
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 ...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...